Barclays Cuts Danaher (NYSE:DHR) Price Target to $240.00

Danaher (NYSE:DHR) had its target price decreased by stock analysts at Barclays from $275.00 to $240.00 in a research note issued on Thursday,Benzinga reports. The brokerage presently has an “equal weight” rating on the conglomerate’s stock. Barclays‘s price target points to a potential upside of 7.57% from the company’s current price.

A number of other brokerages have also weighed in on DHR. Citigroup lowered their price objective on Danaher from $305.00 to $285.00 and set a “buy” rating on the stock in a report on Monday, January 6th. Stephens reissued an “overweight” rating and set a $315.00 price objective on shares of Danaher in a research note on Wednesday, October 23rd. Stifel Nicolaus raised their price target on shares of Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research note on Wednesday, October 23rd. Jefferies Financial Group dropped their target price on Danaher from $285.00 to $260.00 and set a “buy” rating for the company in a research note on Wednesday. Finally, KeyCorp increased their price target on shares of Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 23rd. Six analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $282.48.

Danaher Price Performance

DHR stock opened at $223.12 on Thursday. The business has a 50 day moving average price of $236.09 and a 200 day moving average price of $253.66. Danaher has a fifty-two week low of $223.00 and a fifty-two week high of $281.70. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. The stock has a market cap of $161.16 billion, a price-to-earnings ratio of 42.58, a PEG ratio of 4.43 and a beta of 0.83.

Danaher (NYSE:DHR) last announced its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. During the same quarter last year, the firm earned $2.09 EPS. Equities research analysts anticipate that Danaher will post 7.5 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Danaher

Several institutional investors have recently modified their holdings of the company. FMR LLC grew its holdings in Danaher by 15.8% in the 3rd quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock worth $6,566,116,000 after buying an additional 3,217,631 shares in the last quarter. Van ECK Associates Corp boosted its position in Danaher by 6,862.7% during the 4th quarter. Van ECK Associates Corp now owns 929,868 shares of the conglomerate’s stock worth $213,452,000 after acquiring an additional 916,513 shares during the period. Massachusetts Financial Services Co. MA increased its holdings in shares of Danaher by 17.6% during the third quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock valued at $996,141,000 after purchasing an additional 535,254 shares during the period. International Assets Investment Management LLC lifted its holdings in Danaher by 40,196.5% in the third quarter. International Assets Investment Management LLC now owns 429,964 shares of the conglomerate’s stock worth $119,539,000 after purchasing an additional 428,897 shares during the period. Finally, Montrusco Bolton Investments Inc. grew its position in Danaher by 30.4% in the 3rd quarter. Montrusco Bolton Investments Inc. now owns 1,705,884 shares of the conglomerate’s stock valued at $465,617,000 after buying an additional 397,671 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.